The efficacy of cidofovir treatment of mice infected with ectromelia (mousepox) virus encoding interleukin-4

Antiviral Research

Volumn 66, Issue 1, 2005, Pages 1-7

  Robbins, Samantha J ^a   Jackson, Ronald J ^a   Fenner, Frank ^a   Beaton, Sandra ^a   Medveczky, Jill ^a   Ramshaw, Ian A ^a   Ramsay, Alistair J ^a,b  

^a Biology and Environment   (Australia)

^b LOUISIANA STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Cidofovir; Immune suppression; Interleukin 4; Mousepox infection

Indexed keywords

CIDOFOVIR; INTERLEUKIN 4;

ANIMAL MODEL; ANIMAL TISSUE; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; DRUG MEGADOSE; ECTROMELIA VIRUS; LETHALITY; MORTALITY; MOUSE; NONHUMAN; POXVIRUS INFECTION; PRIORITY JOURNAL; REVIEW; SINGLE DRUG DOSE; VIRUS INHIBITION; VIRUS REPLICATION;

ANIMALIA; ECTROMELIA VIRUS; POXVIRIDAE;

EID: 15244356314     PISSN: 01663542     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.antiviral.2004.12.003     Document Type: Review

References (34)

1. S. Aung, and B.S. Graham IL-4 diminishes perforin-mediated and increases Fas ligand-mediated cytotoxicity in vivo J. Immunol. 164 2000 3487 3493
2. R.V. Blanden Mechanisms of recovery from a generalized viral infection: mousepox. I. The effects of anti-thymocyte serum J. Exp. Med. 132 1970 1035 1054
3. R.V. Blanden Mechanisms of recovery from a generalized viral infection: mousepox. II. Passive transfer of recovery mechanisms with immune lymphoid cells J. Exp. Med. 133 1970 1074 1089
4. R.V. Blanden, and I.D. Gardner The cell-mediated immune response to ectromelia virus infection. I. Kinetics and characteristics of the primary effector T cell response in vivo Cell Immunol. 22 1976 271 282
5. J. Bradbury Orally available cidofovir derivative active against smallpox Lancet 359 2002 1041
6. M. Bray Pathogenesis and potential antiviral therapy of complications of smallpox vaccination Antiviral Res. 58 2003 101 114
7. M. Bray, M. Martinez, D.F. Smee, D. Kefauver, E. Thompson, and J.W. Huggins Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge J. Infect. Dis. 181 2000 10 19
8. M. Bray, and M.E. Wright Progressive vaccinia Clin. Infect. Dis. 36 2003 766 774
9. R.M. Buller, G. Owens, J. Schriewer, L. Melman, J.R. Beadle, and K.Y. Hostetler Efficacy of oral active ether lipid analogs of cidofovir in a lethal mousepox model Virology 318 2004 474 481
10. G. Chaudhri, V. Panchanathan, R.M.L. Buller, A.J.M. van den Eertwegh, E. Claassen, J. Ziou, R. de Chazal, J.D. Laman, and G. Karupiah Polarized type 1 cytokine response and cell-mediated immunity determine genetic resistance to mousepox Proc. Natl. Acad. Sci. USA 101 2004 9057 9062
11. E. De Clercq, T. Sakuma, M. Baba, R. Pauwels, J. Balzarini, I. Rosenberg, and A. Holý Antiviral activity of phosphonylmethoxyalkyl derivatives of purine and pyrimidines Antiviral Res. 8 1987 261 272
12. E. De Clercq Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections Clin. Microbiol. Rev. 14 2001 382 397
13. E. De Clercq Clinical potential of the acyclic nucleoside phosphonates cidofovir, adefovir, and tenofovir in treatment of DNA virus and retrovirus infections Clin. Microbiol. Rev. 16 2003 569 596
14. F. Fenner Mouse-pox; infectious ectromelia of mice; a review J. Immunol. 63 1949 341 373
15. F. Fenner, and R.M.L. Buller Mousepox N. Nathanson R. Ahmed F. Gonzalez-Scarano D.E. Griffin K.V. Holmes F.A. Murphy H.L. Robinson Viral Pathogenesis 1997 Lippincott-Raven Publishers Philadelphia, PA 535 553
16. Gilead Sciences, Inc., 2000. Package insert. Vistide® (cidofovir injection).
17. R.J. Jackson, A.J. Ramsay, C.D. Christensen, S. Beaton, D.F. Hall, and I.A. Ramshaw Expression of mouse interleukin-4 by a recombinant ectromelia virus suppresses cytolytic lymphocyte responses and overcomes genetic resistance to mousepox J. Virol. 75 2001 1205 1210
18. R.O. Jacoby, P.N. Bhatt, and D.G. Brownstein Evidence that NK cells and interferon are required for genetic resistance to lethal infection with ectromelia virus Arch. Virol. 108 1989 49 58
19. + T lymphocytes and macrophage subsets in the control of a generalised virus infection J. Virol. 70 1996 8301 8309
20. G. Karupiah, J.H. Chen, C.F. Nathan, S. Mahalingam, and J.D. MacMicking Identification of nitric oxide synthase 2 as an innate resistance locus against ectromelia virus infection J. Virol. 72 1998 7703 7706
21. G. Karupiah, T.N. Fredrickson, K.I. Holmes, L.H. Khairallah, and R.M. Buller Importance of interferons in recovery from mousepox J. Virol. 67 1993 4214 4226
22. G. Karupiah, Q.W. Xie, R.M. Buller, C.F. Nathan, C. Duarte, and J.D. MacMicking Inhibition of viral replication by interferon-γ-induced nitric oxide synthase Science 261 1993 1445 1448
23. H.C. Lane, J.L. Montagne, and A.S. Fauci Bioterrorism: a clear and present danger Nat. Med. 7 2001 1271 1273
24. A. Müllbacher, R.T. Hla, C. Museteanu, and M.M. Simon Perforin is essential for the control of ectromelia virus but not related poxviruses in mice J. Virol. 73 1999 1665 1667
25. P.F. Nettleton, J.A. Gilray, H.W. Reid, and A.A. Mercer Parapoxviruses are strongly inhibited in vitro by cidofovir Antiviral Res. 48 2000 205 208
26. J. Neyts, and E. De Clercq Efficacy of (S)-1-(3-hydroxy-2- phosphonylmethoxypropyl) cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice J. Med. Virol. 41 1993 242 246
27. J. Neyts, and E. De Clercq Therapy and short-term prophylaxis of poxvirus infections: historical background and perspectives Antiviral Res. 57 2003 25 33
28. H.C. O'Neill, and M. Brenan A role for early cytotoxic T cells in resistance to ectromelia virus infection in mice J. Gen. Virol. 68 1987 2669 2673
29. D.C. Quenelle, D.J. Collins, W.B. Wan, J.R. Beadle, K.Y. Hostetler, and E.R. Kern Oral treatment of cowpox and vaccinia virus infections in mice with ether lipid esters of cidofovir Antimicrob. Agents Chemother. 48 2004 404 412
30. I.A. Ramshaw, A.J. Ramsay, G. Karupiah, M.S. Rolph, S. Mahalingam, and J.C. Ruby Cytokines and immunity to viral infections Immunol. Rev. 159 1997 119 135
31. + T cells Microbes Infect. 5 2003 923 932
32. D.F. Smee, K.W. Bailey, and R.W. Sidwell Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir Antiviral Chem. Chemother. 12 2001 71 76
33. D.F. Smee, R.W. Sidwell, D. Kefauver, M. Bray, and J.W. Huggins Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses Antimicrob. Agents Chemother. 46 2002 1329 1335
34. V.P. Smith, and A. Alcami Inhibition of interferons by ectromelia virus J. Virol. 76 2002 1124 1134